Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO trial
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26480
Abstract: In the phase 3 APOLLO trial, daratumumab in combination with pomalidomide and dexamethasone (D‐Pd) significantly reduced the rate of disease progression or death by 37% relative to Pd alone in patients with relapsed/refractory multiple myeloma… read more here.
Keywords: pomalidomide dexamethasone; daratumumab; health; relapsed refractory ... See more keywords